https://mjzanon.com/wp-content/uploads/2025/02/PharmaReportbyMJZanon-RPI2825.pdf🚨 BREAKING: Brazil’s Pharma Trademark Boom – AI, CBD, and High-Stakes IP Wars
Key insights from INPI RPI2825 data (Feb 2025):
🔍 Why This Matters for Pharma & IP Leaders:
✅ AI-Driven Drug Development: 28% of Class 5 (Pharma) filings now integrate AI (e.g., HIY.AI

Healthcare).
✅ CBD Dominance: Montjuic S.A. leads with Erb CBD Pharma Grade (+34% YoY growth!).
🔥 High-Risk Zones: 320+ oppositions in Class 5 – generic vs. branded drug wars escalate.
🌱 Untapped Opportunities: Psychedelics & telemedicine trademarks remain wide open.
📢 Act Now or Lose Ground:
1️⃣ Secure hybrid trademarks (Class 5 + 42 for AI-pharma tools).
2️⃣ Partner with CBD innovators before markets saturate.
3️⃣ Avoid São Paulo’s opposition battlegrounds – use predictive tools like TWS IP AI.
💼 Free Risk Assessment:
👉 Comment “PHARMA IP” or DM me for a custom trademark audit.

👉 REPORT 

🔗 Tag Your Team:
👉 IP Attorneys | 👉 Pharma Execs | 👉 Investors
Data doesn’t lie – but your competitors won’t wait. 🔥
hashtag

hashtag#PharmaTrends hashtag
hashtag#TrademarkStrategy hashtag
hashtag#AIInHealthcare hashtag
hashtag#CBD hashtag
hashtag#BrazilIP
M. J. Zanon
Brazilian IP Attorney | Pharma IP Strategist
📩 [email protected] | 🌐 www.mjzanon.com